Assisteo SAS has been acquired by DomusVi
DomusVi has acquired a 100% stake in Assisteo SAS, a private operator of home care services in France, for US$7 million.
With 23 branches throughout France, Assisteo is one of the three largest private players in France in a market dominated by non-profit organizations. They enjoy a reputation for high quality services and for a very efficient in-house developed IT system.
DomusVi manages 92 nursing homes, 20 home help agencies, six serviced accommodation units and ten establishments offering consultations, surgery and out-patient treatment in France and Quebec.
Oaklins' team in France advised the seller in this transaction. After an auction process, a short exclusivity period was offered to DomusVi who completed the transaction in two months.
Talk to the deal team
Related deals
Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn moreEuroHospital Varna has been acquired by Intermedica Group
EuroHospital Varna has been acquired by Intermedica Group, allowing the business to continue to grow and deliver high-quality healthcare services to its patients. Through the transaction, Intermedica Group expands its healthcare presence and intends to build a new model of integrated personalized care focused on preventive, holistic and digital medicine.
Learn moreOlyos Group has acquired a controlling stake in NewScience
Olyos Group has acquired a controlling stake in NewScience from its founders through a transaction structured in two stages, with the strategic objective of ultimately acquiring 100% of the company. The transaction forms part of NewScience’s international growth strategy and a gradual cash-out process for the founder, who intends to complete a full exit. Olyos intends to retain the management team through a put and call option mechanism and an earn-out linked to NewScience’s 2025 EBITDA.
Learn more